Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
about
The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.The high price of anticancer drugs: origins, implications, barriers, solutions.Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CMLRadotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review.Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence.
P2860
Q30491107-E0950190-26E2-421B-9CB9-953159CB4D37Q33756387-94C4DB89-1F0A-4513-AFA3-1222B371BE99Q38909657-5D7D047B-E820-48F7-A0B5-027C91964023Q39457369-14184D7A-F705-48CE-8364-7FF0330E16AEQ42344645-3B9BD810-503B-4D3F-AD15-0555E79B6A63Q42376732-442D557B-3ADA-4011-9834-D8450E09EE52Q47211218-D8F9E2E7-4B33-4FA2-95D0-5ECBB03A37E5Q47656490-A30E144D-1C73-46AD-B000-CD1B47C60E29Q47917650-E4981946-9F7B-400D-A16C-27B7922016B8Q47968789-ACE21BAC-F4FE-4585-9A77-AF44DABDCA9DQ48146023-81C2F4C3-3CFA-4740-8918-748ADEEE7015Q50997822-FBAAF82C-E00E-4BCE-B118-6F61120D9449Q52567954-B83CB569-C2B1-4AEA-86DF-FC381C090C6DQ52677126-8FC4D8A2-4412-4184-B561-76FEE03CCE21Q55005455-17D937D0-D6CD-44D3-98A4-C9A0B6EAB172
P2860
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness of Tyrosine ...... Imatinib in the United States.
@en
Cost-effectiveness of Tyrosine ...... Imatinib in the United States.
@nl
type
label
Cost-effectiveness of Tyrosine ...... Imatinib in the United States.
@en
Cost-effectiveness of Tyrosine ...... Imatinib in the United States.
@nl
prefLabel
Cost-effectiveness of Tyrosine ...... Imatinib in the United States.
@en
Cost-effectiveness of Tyrosine ...... Imatinib in the United States.
@nl
P2093
P2860
P50
P921
P356
P1476
Cost-effectiveness of Tyrosine ...... Imatinib in the United States.
@en
P2093
Bengt Simonsson
Charles A Schiffer
Dietger Niederwieser
Ekkehard Eigendorff
Francois Guilhot
Francois-Xavier Mahon
Jane F Apperley
Jiri Mayer
Joelle Guilhot
Martin C Müller
P2860
P356
10.1093/JNCI/DJW003
P407
P577
2016-03-04T00:00:00Z